Drug Trial Radar · NCT06707610
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
234
Planned (sponsor's estimate)
Start
Feb 10, 2025
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Shanghai Allink Biotherapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK202 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK202.
Conditions
- Advanced Cancer
- Advanced Solid Tumor
Interventions
ALK202Drug
Administered intravenously, once every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of ALK202 in adult participants with advanced solid tumors; To determine the maximum tolerated dose (MTD); To determine the recommended dose(s) of ALK202 for subsequent clinical studies.Time frame: Approximately 36 months
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
D&H Cancer Research Center Llc
Margate, Florida · Recruiting
Next Oncology
Fairfax, Virginia · Recruiting
Scientia Clinical Research Ltd
Randwick, New South Wales, Australia · Recruiting
Macquarie University
Sydney, New South Wales, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.